1.Li Y, Tang HL, Hu YF*, Xie HG, The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients, J Thromb Haemost, 2012, 10(2):199-206
2.Yao Ya, Ma CH, Tang HL, Hu YF*, Influence of follicle-stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: A meta-analysis, Mol Genet Metab, 2011, 103: 388-393
3.Tang HL, Xie HG, Yao Y, Hu YF*, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non-expressers than expressers, Pharmacogenetics and Genomics, 2011, 21(11): 713–720
4.Tang HL, Ma LL, Xie HG, Zhang T, Hu YF*, Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis, Pharmacogenetics and Genomics, 2010,20(9): 525-531
5.Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH, Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation, Clin Exp Pharmacol Physiol, 2006,33(11):1093-1098, Clin Exp Pharmacol Physiol, 2006,33(11):1093-1098
6.Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH, Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects, Xenobiotica, 2007, 37 (3):315-327
7.Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH, CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population, Clin Chim Acta, 2005,353(1-2):187-192
8.谢吉科,颜妍,陈朋,胡永芳.北京清华长庚医院门诊老年患者多重用药调查及潜在不适当用药分析[J].临床药物治疗杂志,2018,16(11):52-55+60